Episode 222 – AI is Moving Drug Discovery From Prediction to Generation
The Big Unlock · Alex Zhavoronkov, Founder, CEO and CBO, Insilico Medicine
In this episode, Alex Zhavoronkov, Founder, CEO and CBO of Insilico Medicine, explores how generative AI is reshaping drug discovery and opening new possibilities in longevity research. He explains how AI can move pharmaceutical R&D from searching for promising molecules toward generating molecules with desired properties, while orchestrating specialized models and agents across the drug development lifecycle. Insilico combines AI models across biology, chemistry, and clinical development to move from target identification to drug candidates faster, with multiple programs now in clinical trials.
Alex argues that AI can dramatically expand the number of experiments researchers can conduct, but the complexity of biology means failure remains inevitable and real-world validation is essential. He discusses the industry’s shift from predictive AI to generative and agentic systems capable of orchestrating t
In this episode, Alex Zhavoronkov, Founder, CEO and CBO of Insilico Medicine, explores how generative AI is reshaping drug discovery and opening new possibilities in longevity research. He explains how AI can move pharmaceutical R&D from searching for promising molecules toward generating molecules with desired properties, while orchestrating specialized models and agents across the drug development lifecycle. Insilico combines AI models across biology, chemistry, and clinical development to move from target identification to drug candidates faster, with multiple programs now in clinical trials.
Alex argues that AI can dramatically expand the number of experiments researchers can conduct, but the complexity of biology means failure remains inevitable and real-world validation is essential. He discusses the industry’s shift from predictive AI to generative and agentic systems capable of orchestrating t
Loading content...
Read the full transcript
Matterfact has every podcast on Apple Podcasts and Spotify: 700K+ channels, 120M+ episodes.
The candid version is on a podcast,
not the earnings call.
Matterfact turns the conversations your coverage is already having into a searchable, citable record — across every episode, not just this one.